Two decades of advancing safe and effective cell-based therapies: a review of the impact, promise, and current limitations of USA regulation 21 CFR Part 1271.

Abstract

Over the past 20 years, USA regulation 21 CFR Part 1271 has served as the cornerstone regulation for human cells, tissues, and cellular and tissue-based products (HCT/Ps) in the United States. Designed to ensure public health safety while fostering innovation, the framework has significantly shaped the development and oversight of regenerative medicine. This paper examines the evolution of 21 CFR Part 1271 since its inception, highlighting key amendments, milestones, and regulatory challenges. It explores its impact on the industry, focusing on case studies that underscore its influence on clinical translation and commercialization. The analysis shows that 21 CFR Part 1271 addresses ongoing controversies, such as compliance and enforcement challenges, and discusses how emerging technologies like exosomes, gene editing, and bioprinting may reshape its future. By reflecting on two decades of regulatory experience, this paper provides insights into the successes and limitations of 21 CFR Part 1271 and proposes pathways for its modernization to address the growing complexity of regenerative medicine.